Thursday, 24 September 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 9, 2026

Life Sciences Analytics Market Advances to US$ 23.17 Billion by 2033 on AI-Driven Drug Discovery and Cloud Platforms Says Astute Analytica

View original at finance.yahoo.com
Life Sciences Analytics Market Advances to US$ 23.17 Billion by 2033 on AI-Driven Drug Discovery and Cloud Platforms Says Astute Analytica AstuteAnalytica India Pvt…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The global life sciences analytics market was valued at 11.10 billion in 2024 and is expected to reach US$ 23.17 billion by 2033, growing at a CAGR of 8.52% from 2025 to 2033

    80% confidence

  • Growth is fueled by the adoption of advanced analytics platforms, AI-driven modules, and cloud-based solutions that optimize drug discovery, clinical trials, pharmacovigilance, and precision medicine

    80% confidence

  • North America's leadership in life sciences analytics stems from strong research infrastructure, extensive clinical trials, and a concentration of top-tier academic institutions

    80% confidence

  • Leading players such as Roche, Johnson & Johnson, AstraZeneca, and Merck are investing heavily in specialized analytics tools and dedicated data teams to accelerate real-time decision-making, improve patient stratification, and enhance treatment outcomes

    80% confidence

Data points we hold from this source

AstraZeneca AB · solution count9 cloud_solutions
Sanofi · dashboard count3 unified_dashboards
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Enterprise AI Agents Go Mainstream, But Trustworthy Data Access Lags Adoption
A wave of enterprise AI agent activity — fresh funding (Latitude's $35M Series A), a run of CB Insights CEO interviews spotlighting fintech- and healthcare-focused agent startups (Covecta, Penguin AI, Maisa AI), and major platform partnerships (Microsoft-Mistral, Manulife-Microsoft AI governance, Siemens-NVIDIA agentic EDA, Box's agent security controls) — signals agentic AI moving from pilot to production across financial and enterprise workflows. Yet Google Cloud's own research shows adoption is outrunning data readiness (companies average AI access to only 45% of their data, with 'data laggards' capped near 30%), while insider selling at incumbent C3.ai hints at mixed investor conviction even as the broader ecosystem accelerates.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,983
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,983 facts checked against source5,305 source documents archived
Query this data → isubstrate.com
Life Sciences Analytics Market Advances to US$ 23.17 Billion by 2033 on AI-Driven Drug Discovery and Cloud Platforms Says Astute Analytica — Source | Via News | ViaNews EU